Quarterly report · Q1
4587.TEDINET S100TFRV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.2bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥28.7bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥5.0bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | −¥1.1bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | −¥267m | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥1.1bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥400m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥843m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥249m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥843m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥249m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥69.6bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥69.5bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥59.8bn | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥29.7bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥29.1bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥40.0bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.3bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥40.0bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥40.3bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.8bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥27.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.5bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥1.9bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥12.4bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥7.7bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥10.4bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥1.3bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥381m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥757m | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥264m | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.1bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-6.5 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.41 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-1.92 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-6.5 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.38 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-1.92 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 57.4% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 58.1% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 53.2% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥75m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥75m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥521m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥521m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥955m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥3.8bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥3.7bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥75m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥121m |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥4.3bn |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥4.2bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥75m |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | −¥1.1bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥3m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥978m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥978m |
| jpcrp040300-q1r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥381m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥4.0bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥4.0bn |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q1r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥136m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥5.0bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥3m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | −¥244m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 513
| Item | Context | Value | Unit |
|---|---|---|---|
| Total transactions with owners IFRS | CurrentYTDDuration_TreasurySharesIFRSMember | -58000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | 6539253000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | -6539253000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember | 8111000 | JPY |
| Total transactions with owners IFRS | CurrentYTDDuration | 8111000 | JPY |
| Equity IFRS | CurrentQuarterInstant_ShareCapitalIFRSMember | 3956738000 | JPY |
| Equity IFRS | CurrentQuarterInstant_CapitalSurplusIFRSMember | 4558543000 | JPY |
| Equity IFRS | CurrentQuarterInstant_TreasurySharesIFRSMember | -1085605000 | JPY |
| Equity IFRS | CurrentQuarterInstant_RetainedEarningsIFRSMember | 33501400000 | JPY |
| Equity IFRS | CurrentQuarterInstant_OtherComponentsOfEquityIFRSMember | -946349000 | JPY |
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 39984726000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 39984726000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | -399914000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | -1104054000 | JPY |
| Depreciation and amortization ope cf IFRS | Prior1YTDDuration | 608556000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYTDDuration | 631660000 | JPY |
| Interest and dividend income ope cf IFRS | Prior1YTDDuration | -5663000 | JPY |
| Interest and dividend income ope cf IFRS | CurrentYTDDuration | -294000 | JPY |
| Interest expenses ope cf IFRS | Prior1YTDDuration | 58966000 | JPY |
| Interest expenses ope cf IFRS | CurrentYTDDuration | 64636000 | JPY |
| Foreign exchange loss gain ope cf IFRS | Prior1YTDDuration | -162793000 | JPY |
| Foreign exchange loss gain ope cf IFRS | CurrentYTDDuration | -82624000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | Prior1YTDDuration | 34262000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | CurrentYTDDuration | 90328000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | 10438145000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | 242281000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -17771000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -334221000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -343019000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -158656000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | Prior1YTDDuration | -1369000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | CurrentYTDDuration | -2291000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -117278000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -211950000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 10092120000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | -865186000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 5663000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 294000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -46289000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -50663000 | JPY |
| Income taxes paid ope cf IFRS | Prior1YTDDuration | -2314451000 | JPY |
| Income taxes paid ope cf IFRS | CurrentYTDDuration | -1007503000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 7737043000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | -1923059000 | JPY |
| Proceeds from sale of investment securities inv cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from sale of investment securities inv cf IFRS | CurrentYTDDuration | 10935460000 | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YTDDuration | 1560000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYTDDuration | 1561000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -366620000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -484412000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |